The CHECKMATE-7FL trial evaluates the efficacy of nivolumab, an anti-PD-1 antibody, in combination with neoadjuvant endocrine therapy for HR-positive, HER2-negative early breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.